SLC5A2 and diabetes mellitus: Evidence obtained from a number of cardiovascular trials (Anker et al., 2021; Fitchett et al., 2019) demonstrates that SGLT2 inhibitors reduce the incidence of HF in patients with diabetes by ∼40% and also indicates that the drugs have significant cardioprotective effects in the absence of diabetes.